Skip to main content Skip to secondary navigation
Journal Article

Does androgen deprivation therapy in men with prostate cancer increase cardiovascular morbidity?

The use of ADT for the treatment of prostate cancer has increased dramatically since the recognition of its utility more than 60 years ago. The introduction of gonadotropin-releasing hormone (GnRH) agonists in the mid-1980s provided new medical treatment options for patients with metastatic prostate cancer. The increased use of GnRH agonists is attributable to their proven benefit when used in conjunction with radiation therapy for the treatment of early prostate cancer, and to the early detection of local recurrence by widespread PSA screening. A growing body of evidence, however, indicates that ADT is associated with increased rates of cardiovascular events.
Steven M Corsello
Philip W Kantoff
Journal Name
Nature Clinical Practice Urology
Publication Date
February, 2008